Abstract:Background Atopic dermatitis (AD) is a chronic recurrent inflammatory disease, and dupilumab, a human monoclonal antibody, is the firstly approved biological drug for AD. Psoriasiform erythema (PE) during dupilumab treatment in adults has been reported. This study describes the risk of PE in children after initiation of dupilumab treatment. Objectives To evaluate the de novo cytokines gene expression in the transition of atopic dermatitis symptoms to psoriasiform erythema during dupilumab treatment in children. Methods Two 17-year-old teenage twin patients with AD were included in this study who developed psoriasiform erythema after initiation of dupilumab. The lesional skin biopsy specimens were obtained for the histopathological investigation and RNA Fluorescence In Situ Hybridization (RNA-FISH). Dermoscopy, cytometry (cytokine detection in the blood), and blood investigations were completed for the pedigree and the lesioned descriptions. Results Two twin patients with AD presented with erythematic scaly plaques on the back, scalp, abdomen, and extensor extremities after 20 weeks of dupilumab treatment. The transitional change of AD to psoriasiform erythema treated with dupilumab was observed. Our subjects' dermoscopy showed pinpoint bleeding and white scales on pink background. Histopathology features showed psoriasiform hyperplasia, epidermal hyperplasia (acanthosis), ectatic capillaries, perivascular lymphocytes infiltration, and parakeratosis, with the absence of the granular cell layer. mRNA (RNA-FISH) cytokines gene expression showed a significantly high concentration of IL-17A. Blood investigation results showed a high concentration of (Immunoglobulin E) IgE and Eosinophils, and cytokines detection in blood showed IL-5,6 and IL-17 in one patient; however, only IL-5 in another patient. The dupilumab was discontinued and initiated with Baricitinib. Baricitinib showed a significant reduction in skin lesions. Conclusion Psoriasiform erythema can appear during dupilumab treatment in atopic dermatitis children. Potently, by suppressing skewed Th2 activation in patients with AD, the balance might shift toward Th1/Th17 predominance, and psoriasis develops. Baricitinib is a potential drug for psoriasiform erythema with significant therapeutic effects.

[Expression of DUOX2 in Psoriasis and Atopic Dermatitis Lesion].

Identification of Candidate Genes in Atopic Dermatitis Based on Bioinformatic Methods

Duox2 Expression is Increased in Barrett Esophagus and Cancerous Tissues of Stomach and Colon

Comparative Expression of PEDF and VEGF in Human Epidermal Keratinocytes and Dermal Fibroblasts: from Normal Skin to Psoriasis.

Expression of Wnt5a,Frizzled2 and Cyclic GMP-dependent Protein Kinase in the Skin Lesions of Psoriasis Vulgaris

OAS1, OAS2, and OAS3 Contribute to Epidermal Keratinocyte Proliferation by Regulating Cell Cycle and Augmenting IFN-1‒Induced Jak1‒Signal Transducer and Activator of Transcription 1 Phosphorylation in Psoriasis.

Expression of Toll-like Receptor 2 and 4 in Psoriatic Lesions

Quantitative Proteomic Profile of Psoriatic Epidermis Identifies OAS2 as a Novel Biomarker for Disease Activity

Study on the Expression and Potential Effect of PD-L1mRNA and PD-L2mRNA in Oral Lichen Planus

Expression of Peroxisome Proliferator-Activated Receptor Β/δ in Psoriatic Epidermal Keratinocytes

[Expression of E-cadherin, Beta-Catenin and Cyclin D1 in Epidermal Skin Lesions of Patients with Active Psoriasis Vulgaris].

Exploration of the Potential Mechanism of the Common Differentially Expressed Genes in Psoriasis and Atopic Dermatitis

Toll-like Receptors and Antimicrobial Peptides Expressions of Psoriasis: Correlation with Serum Vitamin D Level

Expression of Psoriasin in Actinic Keratosis, Bowen's Disease and Squamous Cell Carcinoma and Its Significance

[Effect of Topical Tacrolimus Ointment on Expression of Toll-like Receptors 2 and 4 in Lesional Atopic Dermatitis Skin].

Correlation and Clinical Significance of HBD-2 and CXCL-1/2 Levels at Skin Lesions with Psoriasis Vulgaris Severity

TLR2 and TLR4 expression of keratinocytes in atopic dermatitis lesion

Expression of glucocorticoid receptor-α in the epidermis of patients with psoriasis vulgaris

The Long Non-Coding RNA and Mrna Expression Profiles in Keratinocytes from Patients with Psoriasis Vulgaris.

[Expression of Psoriasin in Mycosis Fungoides and Its Significance].

Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab